Sign inCreate account

Report workspace tools

NCT06687564RECRUITINGanonymous

Role of ACTG2 Variants in Smooth Muscle Determination and Function in Pediatric Intestinal Pseudo-obstruction.

Sponsor

Source record

University Hospital, Grenoble

Phase

Source record

NA

Modality

AI-normalized

cell therapy

Target

AI-normalized

Biopsy

Indication / condition

AI-normalized

PIPO

Intervention

Source record

Biopsy

Source & freshness

Source record

NCT ID

NCT06687564

Original source

ClinicalTrials.gov

Source last updated

May 27, 2026

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06687564

Title

Role of ACTG2 Variants in Smooth Muscle Determination and Function in Pediatric Intestinal Pseudo-obstruction.

Sponsor

University Hospital, Grenoble

Status

RECRUITING

Phase

NA

Condition raw

PIPO

Condition normalized

PIPO

Modality raw

cell therapy

Modality normalized

cell therapy

Target raw

Biopsy

Target normalized

Biopsy

Interventions

Biopsy

Public preview

Source record

The primary objective of this study is to describe the transcriptional impact of R178, R257, R40 or A136 variants of the ACTG2 gene on iPS differentiation mechanisms up to organoids derived from PIPO patient samples versus those derived from control / WT patients (generation of IPS from cultured cell lines), at different stages of their experimental ex vivo development.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Role of ACTG2 Variants in Smooth Muscle Determination and Function in Pediatric Intestinal Pseudo-obstruction.

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT06687564

Status

RECRUITING

Phase

NA

Sponsor

University Hospital, Grenoble

Executive brief

Investment-Ready Snapshot

The primary objective of this study is to describe the transcriptional impact of R178, R257, R40 or A136 variants of the ACTG2 gene on iPS differentiation mechanisms up to organoids derived from PIPO patient samples versus those derived from control / WT patients (generation of IPS from cultured cell lines), at different stages of their experimental ex vivo development.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 27, 2026
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06687564

Indication

PIPO

Modality

cell therapy

Target

Biopsy

Intervention

Biopsy

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.